Aerie Pharmaceutical (AERI) 39.07 $AERI Biotechnology

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aerie Pharmaceutical (AERI) 39.07 $AERI

Biotechnology Companies Reaching New Milestones
PR Newswire - Thu Sep 22, 8:00AM CDT
Transparency Market Research published a report on the global biotechnology market and claiming that this vibrant market is expected to grow at an average annual growth rate of CAGR rate of 11.6% by the end of 2017. The data provided indicates that in 2011, the market was valued at roughly $216.5 billion, yet major changes in the way the industry operates and innovative developments in the sector, have pushed values to reach $414.5 billion by the end of 2017. Allergan PLC (NYSE: AGN), Tobira Therapeutics, Inc. (NASDAQ: TBRA), MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), Aerie Pharmaceuticals Inc. (NASDAQ: AERI), Puma Biotechnology Inc. (NYSE: PBYI).
AGN: 243.94 (+0.51), MBVX: 4.72 (-0.04), AERI: 39.07 (+1.02), TBRA: 39.11 (-0.39), PBYI: 68.08 (+2.10)

Company News for September 16, 2016
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 9:10AM CDT
Companies in the News are: GT,AERI,LAKE,ACRX
ACRX: 3.68 (+0.10), GT: 32.30 (-0.12), LAKE: 10.20 (+0.01), AERI: 39.07 (+1.02)

Blog Coverage Aerie Pharma Glaucoma Drug "Roclatan" Surpasses Primary Goals at End Phase III Trials
ACCESSWIRE - Fri Sep 16, 8:16AM CDT
LONDON, UK / ACCESSWIRE / September 16, 2016 / Active Wall St. blog coverage looks at the headline from Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) as the company announced on September 14, 2016, that the Phase III clinical trial results for its eye pressure drug "Roclatan" were positive and achieved its endpoint. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
PFE: 34.26 (+0.11), AERI: 39.07 (+1.02)

Pharma Stock Roundup: Acquisitions & Deals Pick Up Pace, Aerie Up on Positive Data
Arpita Dutt - Zacks Investment Research - Fri Sep 16, 8:04AM CDT
While Bayer (BAYRY) has signed a merger agreement with Monsanto, Allergan will be acquiring Vitae.
AGN: 243.94 (+0.51), PFE: 34.26 (+0.11), AZN: 33.97 (-0.31), AERI: 39.07 (+1.02), TEVA: 51.47 (+0.24), SNY: 38.35 (-0.22)

Aerie Pharmaceuticals Raises $125 Million in Public Offerings
BusinessWire - Fri Sep 16, 5:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the pricing of a registered underwritten public offering of $75 million of shares of its common stock at a price to the public of $29.50 per share, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering was upsized by $25 million over the offering amount anticipated to be sold as previously announced. This is in addition to $50 million raised separately through the completion and full utilization of an at-the-market (ATM) program with Cantor Fitzgerald & Co. filed prior to market open on September 15, 2016. Total gross proceeds raised through these offerings were $125 million. The shares sold through the $50 million ATM program will be issued on or about September 20, 2016, and the $75 million public offering is expected to close on or about September 21, 2016, subject to the satisfaction of customary closing conditions.
AERI: 39.07 (+1.02)

Apple, Goodyear and Noble Energy rise; Wells Fargo slumps
AP - Thu Sep 15, 4:18PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday:
NBL: 33.02 (-1.01), GT: 32.30 (-0.12), GPN: 75.42 (-0.63), AMCX: 52.38 (+1.40), VFC: 56.95 (+0.07), AERI: 39.07 (+1.02), WFC: 45.74 (+0.02), AAPL: 112.71 (-1.91)

Aerie Pharmaceuticals Announces Public Offering of Common Stock
BusinessWire - Thu Sep 15, 3:05PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock.
AERI: 39.07 (+1.02)

Aerie (AERI) Stock Up on Positive Phase III Data on Roclatan
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 8:04AM CDT
Aerie (AERI) announced successful 90-day primary efficacy data from a phase III study, Mercury 1, on its eye pressure drug, Roclatan.
ANIP: 66.64 (-0.17), PFE: 34.26 (+0.11), AERI: 39.07 (+1.02), ANIK: 46.92 (-1.07)

Aerie Pharmaceuticals Reports Positive Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results
BusinessWire - Wed Sep 14, 3:01PM CDT
--Conference Call and Webcast Today, September 14, at 5:00 p.m. ET
AERI: 39.07 (+1.02)

Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for Rhopressa(TM) (netarsudil ophthalmic solution) 0.02%
BusinessWire - Tue Sep 06, 3:01PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Rhopressa(TM) (netarsudil ophthalmic solution) 0.02%. Rhopressa(TM) is a novel once-daily eye drop designed to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The filing includes the results of the first two Phase 3 registration trials for Rhopressa(TM), named Rocket 1 and Rocket 2.
AERI: 39.07 (+1.02)

Aerie (AERI) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:08AM CDT
Aerie (AERI) posted a wider-than-expected loss of 87 cents in the second-quarter 2016 loss.
AGEN: 6.90 (-0.10), ANIP: 66.64 (-0.17), AERI: 39.07 (+1.02), ANIK: 46.92 (-1.07)

Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
BusinessWire - Thu Aug 04, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Canaccord Genuity Growth Conference on Wednesday, August 10, 2016 at 12:30 p.m. Eastern Time in Boston, MA. Dr. Anido will provide an Aerie overview and business update.
AERI: 39.07 (+1.02)

Aerie Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Wed Aug 03, 3:01PM CDT
--Mercury 1 Phase 3 Topline Readout for Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Expected in September 2016
AERI: 39.07 (+1.02)

Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:30AM CDT
Can drug stocks Zoetis, Conatus and others pull a surprise when they report their Q2 results on Aug 3?
ZTS: 51.51 (-0.12), JNJ: 118.81 (-0.65), GILD: 81.37 (-0.15), GERN: 2.20 (-0.02), CNAT: 2.11 (-0.05), AERI: 39.07 (+1.02), EXEL: 14.89 (+0.15)

What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:38PM CDT
Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report second-quarter 2016 results after the market closes on Aug 3.
IPXL: 26.49 (+0.05), IRWD: 15.72 (-0.15), AERI: 39.07 (+1.02), EXEL: 14.89 (+0.15)

Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa(TM)(netarsudil ophthalmic solution) 0.02%
BusinessWire - Thu Jun 16, 5:30AM CDT
---Rocket 4 Designed for EU Filing; Not Required for US NDA Filing-
AERI: 39.07 (+1.02)

Aerie Pharmaceuticals to Participate in Two Investor Conferences in June
BusinessWire - Thu Jun 02, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that company management will present an overview of the company at the following conferences in June.
AERI: 39.07 (+1.02)

Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan(TM)(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
BusinessWire - Thu May 05, 5:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced the completion of patient enrollment in the Company's initial Phase 3 registration trial ("Mercury 1" of Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Roclatan(TM) is a fixed dose combination of Aerie drug Rhopressa(TM) (netarsudil ophthalmic solution) 0.02% and latanoprost, the most widely prescribed PGA (prostaglandin analogue). Mercury 1 has total enrollment of approximately 690 patients in this three-arm study, designed to demonstrate superiority of Roclatan(TM) to each of its two components, all dosed once daily in the evening. The range for the primary endpoint evaluates patients with maximum baseline IOPs ranging from above 20 to below 36 mmHg (millimeters of mercury). Mercury 1, which commenced in September 2015 is a twelve-month safety trial with a 90-day interim efficacy readout that is expected in the third quarter of 2016. In March 2016, the Company commenced a second Phase 3 registration trial for Roclatan(TM), Mercury 2, which is a 90-day efficacy trial, and also plans to commence in the first half of 2017 a third Phase 3 clinical trial for Roclatan(TM), named Mercury 3, which will be designed to facilitate regulatory approval and commercialization in Europe.
AERI: 39.07 (+1.02)

Aerie Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
BusinessWire - Wed May 04, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday, May 11, 2016 at 3:00 p.m. Pacific Time in Las Vegas, NV. Dr. Anido will provide an Aerie overview and business update.
AERI: 39.07 (+1.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 116

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
Five SEAL Medal of Honor Signatures, One Charity Lot

Updated Category News Views 45

A single rifle can carry a staggering amount of meaning when the names on it belong to all five living U.S. Navy SEAL Medal of Honor recipients. Rock Island Auction Company plans to offer that one-of-a-kind custom precision rifle during its December 4–6, 2026 Premier Firearms Auction, and the financial arrangement is unusually clean: 100% of proceeds are slated for the...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 186

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 179

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
Allstate's October Cat Loss Lands at $232 Million Net

Updated Category News Views 75

October’s weather bill arrived without much poetry: $232 million in estimated catastrophe losses at Allstate. Reported on November 19, that figure falls to $184 million after tax, and it deserves a clear-eyed read rather than the usual insurance-stock theatrics. A single monthly catastrophe tally is not a verdict on the company, but it is absolutely part of the...

Continue Reading
Lieda Shadwick’s Career Education Work Earns 2026 Honor

Updated Category News Views 21

Twenty-six years in classrooms is not the sort of accomplishment that needs fireworks to carry weight. Lieda A. Shadwick’s recognition as The Inner Circle’s 2026 Educator of the Year points to a career built around a stubbornly important idea: students need more than academic vocabulary if they are going to navigate work, leadership, and business with any confidence....

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 153

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 174

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 190

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Century Lithium Clears a Crucial Nevada Permit Gate

Updated Category News Views 65

Permitting news rarely rings a cash register, but it can stop one from being bolted shut. Century Lithium has received confirmation from the Bureau of Land Management’s Tonopah Field Office that baseline studies for its wholly owned Angel Island lithium project in Esmeralda County, Nevada, are complete. The agency also set the project on the Environmental Impact...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growth of the Global Gifts Retailing Market

Updated Category News Views 120

The Gifts Retailing Market is Evolving Rapidly The global gifts retailing industry is projected to experience substantial growth, with estimates indicating an increase of USD 11.01 billion from 2024 to 2028. Several influential factors are driving this trend, notably the rising demand for seasonal decorations and a stronger gifting culture. As consumers increasingly...

Continue Reading
Exploring the Risks Behind the Monumental Rise of Big Tech

Updated Category News Views 163

Understanding the Current Landscape of Big Tech Investment In recent discussions about the tech industry, significant concerns have bubbled to the surface regarding the sustainability of current market valuations. Analysts have pointed out that the optimism surrounding the surge in equity prices may be fueled by unrealistic expectations. John Hussman notably remarked on...

Continue Reading
Senator Markwayne Mullin Makes Notable Stock Purchase in LPL

Updated Category News Views 246

Senator Markwayne Mullin's Recent Stock Transactions Recent financial disclosures reveal that Senator Markwayne Mullin has made a significant investment in LPL Financial Holdings Inc (NASDAQ: LPLA). The purchase, valued between $233,016 and $670,000, was filed recently and adds to his active trading portfolio. This transaction indicates Mullin's ongoing interest in the...

Continue Reading
Pathward Financial: Sale of Insurance Business Extended

Updated Category News Views 123

Pathward Financial, Inc. (NASDAQ: CASH), known as Meta Financial Group in the past, extended the closing of its commercial insurance premium finance business sale to October 22, from an initial deadline of October 1. Traders were quick to sniff out that this delay wasn’t just a minor hiccup—it pointed to deeper operational challenges. Delays and What They Mean for...

Continue Reading
Vallourec's Major Supply Order from ADNOC Signals Growth

Updated Category News Views 198

Vallourec's Major Supply Agreement with ADNOC Vallourec, a global leader in premium seamless tubular solutions, has successfully secured a significant order from the Abu Dhabi National Oil Company (ADNOC). This order includes supplying over 30,000 tons of carbon steel tubulars and related accessories, prominently featuring VAM premium connections. This transaction forms...

Continue Reading